bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
2.060
+0.010 (0.49%)
At close: Nov 7, 2025, 4:00 PM EST
2.220
+0.160 (7.77%)
After-hours: Nov 7, 2025, 7:57 PM EST
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.27M in the quarter ending June 30, 2025, a decrease of -47.05%. This brings the company's revenue in the last twelve months to $7.68M, up 4.99% year-over-year. In the year 2024, bioAffinity Technologies had annual revenue of $9.36M with 269.68% growth.
Revenue (ttm)
$7.68M
Revenue Growth
+4.99%
P/S Ratio
0.15
Revenue / Employee
$134,755
Employees
57
Market Cap
9.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BIAF News
- 2 days ago - bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume - Business Wire
- 11 days ago - bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases - Business Wire
- 19 days ago - bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 - Business Wire
- 23 days ago - bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer - Business Wire
- 24 days ago - bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Business Wire
- 4 weeks ago - WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 4 weeks ago - bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Business Wire
- 4 weeks ago - WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire